<div id="readability-page-1"><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>The latest announcement is out from Soligenix ( (SNGX) ). On February 12, 2026, Soligenix issued a shareholder update outlining clinical and corporate progress across its rare disease pipeline, including the actively enrolling confirmatory Phase 3 FLASH2 trial of HyBryte in early-stage cutaneous T‑cell lymphoma, which has reached 66 of 80 patients and is delivering blinded response rates above design assumptions ahead of an interim analysis expected in the second quarter of 2026. The company also highlighted encouraging Phase 2a data for SGX945 in Behçet’s disease and SGX302 in psoriasis, reiterated its intent to pursue ex‑U.S. partnerships and broader cutaneous indications, and said its current financing strategy and roughly $11 million in available capital should support operations and key milestones through 2026 as it targets a combined multi‑billion‑dollar annual sales opportunity for its pipeline. The most recent analyst rating on (SNGX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page. Spark’s Take on SNGX Stock According to Spark, TipRanks’ AI Analyst, SNGX is a Neutral. The score is held down primarily by very weak financial performance (no revenue, persistent losses, and ongoing cash burn). Technical indicators are neutral-to-soft with price below key moving averages and a negative MACD. Corporate events provide some support via regained Nasdaq compliance, but the new ATM facility underscores continued reliance on external financing, while valuation metrics are constrained by negative earnings and no dividend. To see Spark’s full report on SNGX stock, click here. More about Soligenix Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with unmet medical need. Its lead asset HyBryte, a synthetic hypericin-based photodynamic therapy, targets early-stage cutaneous T‑cell lymphoma, while SGX302 extends the same active ingredient into psoriasis and SGX945 addresses oral ulcers in Behçet’s disease, positioning the company in niche oncology and immune‑mediated markets. Average Trading Volume: 301,470 Technical Sentiment Signal: Sell Current Market Cap: $11.3M See more data about SNGX stock on TipRanks’ Stock Analysis page.</div>

Soligenix (SNGX) provided a shareholder update on February 12, 2026, detailing progress in its rare disease pipeline, including the Phase 3 FLASH2 trial for HyBryte in cutaneous T-cell lymphoma, which has enrolled 66 of 80 patients. The company reported positive Phase 2a data for SGX945 and SGX302, plans for ex-U.S. partnerships, and has approximately $11 million in capital to support operations through 2026. Analysts rate SNGX stock as a Buy with a $10.00 target, though concerns about financial performance persist, leading to a Neutral rating from Spark's AI Analyst.

Tip Ranks

iShares US Pharma

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Soligenix

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VG Health

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Soligenix Provides Shareholder Update on Rare Disease Pipeline